---
title: 'Life Sciences Daily Summary: What Happened on November 18, 2026'
headline: Isomorphic Labs raises $5 billion as Sellas reports AML survival benefit
description: MSD ended its nemtabrutinib program, AriBio reported a subgroup-only
  Alzheimer’s result, the FDA rejected Summit’s ivonescimab application and the EU
  authorized Rasonque for pancreatic cancer.
url: https://thebench.bio/news/summaries/2026-11-18
topic: all
date: '2026-11-18'
covers:
- '2026-11-18'
date_published: '2026-11-18T12:04:54Z'
date_modified: '2026-11-18T12:04:54Z'
tags:
- Clinical
- Funding
- Industry
- Regulatory
- Software
sources: 11
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 18, 2026

**Isomorphic Labs raises $5 billion as Sellas reports AML survival benefit**

MSD ended its nemtabrutinib program, AriBio reported a subgroup-only Alzheimer’s result, the FDA rejected Summit’s ivonescimab application and the EU authorized Rasonque for pancreatic cancer.

## Today in brief

Isomorphic Labs secured $5 billion in a Series C round, while Sellas reported longer survival in a Phase 3 leukemia trial of its cancer vaccine. [1] [2] [3] MSD stopped nemtabrutinib development after a safety review, and the FDA rejected Summit’s ivonescimab application over questions about whether trial results applied to U.S. patients. [4] [5] [6]

AriBio’s Alzheimer’s drug met the primary endpoint in a prespecified subgroup, not the full study population, and the European Commission authorized Revolution Medicines’ Rasonque for previously treated pancreatic cancer. [7] [8]

## Isomorphic Labs raises $5 billion for its AI drug pipeline

Isomorphic Labs raised $5 billion in a Series C led by Greenoaks Capital and Sequoia Capital. [1] [9] The financing came six months after the company raised $2.1 billion in a Series B round. [9] [10]

Isomorphic said it will use the money to expand its AI drug-design platform, advance its pipeline and build clinical-development infrastructure. [9] [10] The company has reported positive preclinical findings in oncology and immunology, but its internal drug candidates remain before clinical testing. [10] [11]

## Sellas reports longer survival with its leukemia vaccine

Sellas said galinpepimut-S lowered the risk of death by 41% in the Phase 3 REGAL trial for acute myeloid leukemia. [2] [3] Median overall survival was 24 months with the vaccine, compared with 14.7 months with investigator-selected treatment. [2] [3]

The global, open-label trial randomized 126 patients in a second or later remission who were ineligible for stem cell transplant. [3] Sellas plans to discuss an accelerated filing with the FDA and is preparing an application for the first half of 2027. [3]

## MSD ends nemtabrutinib development after safety review

MSD stopped the Phase 3 BELLWAVE-011 trial and ended the broader nemtabrutinib program, including two other Phase 3 studies. [4] An external Data Monitoring Committee advised that the drug’s potential benefits might not outweigh the risks seen in the data. [4]

After reviewing the full dataset, MSD said its safety assessment supported permanently ending the trial. [4] The company is notifying investigators and advising enrolled patients to discuss treatment options with their doctors. [4] MSD plans to share full study results after completing its analyses. [4]

## AriBio’s Alzheimer’s drug met its endpoint in one trial subgroup

AriBio said its Phase 3 POLARIS-AD trial met its primary endpoint in the prespecified group taking AR1001 alone, but not in the full study population. [7] In that subgroup, the CDR-SB score difference was 0.44 points, reported as 31% slower clinical decline. [7]

Across all participants, the CDR-SB difference was not significant, and AR1001 did not significantly improve the ADAS-Cog 13 measure. [7] Four people taking AR1001 and two taking placebo had fatal adverse events. Adverse events led 5.2% of AR1001 recipients to stop treatment. [7] AriBio plans to submit the complete results to the FDA to guide its next steps. [7]

## FDA rejects Summit’s ivonescimab application

The FDA issued Summit Therapeutics a complete response letter, rejecting ivonescimab’s application in its current form. [5] [6] The agency said it could not determine whether the progression-free survival benefit in the Phase 3 HARMONi trial applied to U.S. patients. [5]

North America and Europe accounted for 38% of participants, but patients in China accounted for 93% of progression-free survival events in the primary analysis. [5] The trial met its progression-free survival endpoint but missed its overall survival endpoint. [6]

## EU authorizes Rasonque for previously treated pancreatic cancer

The European Commission authorized Revolution Medicines’ Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one systemic treatment. [8] The authorization allows once-daily oral use whether or not a tumor has an identified RAS mutation. [8]

It covers European Union member states, Liechtenstein, Iceland and Norway. [8] Patient access will depend on national pricing, health-technology assessment and reimbursement decisions. [8]

## The day in numbers

- **$5 billion**: Isomorphic Labs’ Series C financing, the largest biotech venture round in BioCentury’s database. [1]
- **24 months vs. 14.7 months**: Median overall survival reported for Sellas’ galinpepimut-S and best available treatment, respectively. [3]
- **41%**: Sellas’ reported reduction in risk of death in the REGAL trial. [2] [3]

## Sources

1. [Isomorphic raises record $5B round before naming a development candidate](<https://www.biocentury.com/article/661647/isomorphic-raises-record-5b-round-before-naming-a-development-candidate?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-18
2. [Sellas’ AML win strengthens case for cancer vaccines in recurrence prevention](<https://www.biocentury.com/article/661645/sellas-aml-win-strengthens-case-for-cancer-vaccines-in-recurrence-prevention?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-18
3. [SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial](<https://www.biopharminternational.com/view/sellas-cancer-vaccine-galinpepimut-s-overall-survival-phase-3-regal-aml>), BioPharm International, 2026-11-17
4. [MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib](<https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/>), Clinical Trials Arena, 2026-11-18
5. [Summit setback reinforces FDA pushback on China-heavy data](<https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-18
6. [FDA holds Summit to survival bar in ivonescimab CRL](<https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-17
7. [AriBio’s oral Alzheimer’s drug nets Phase III win ](<https://www.clinicaltrialsarena.com/news/aribio-ar1001-alzheimers-pill-phase-iii-polaris-ad/>), Clinical Trials Arena, 2026-11-17
8. [Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer](<https://www.pharmaceutical-technology.com/news/revolution-medicines-rasonque-ec-pancreatic-cancer/>), Pharmaceutical Technology, 2026-11-18
9. [Isomorphic Labs raises $5bn to advance drug pipeline](<https://www.pharmaceutical-technology.com/news/isomorphic-labs-5bn-advance-drug-pipeline/>), Pharmaceutical Technology, 2026-11-18
10. [Isomorphic Labs raises $5B six months after $2.1B round](<https://european-biotechnology.com/latest-news/isomorphic-labs-raises-5b-six-months-after-2-1b-round/>), European Biotechnology, 2026-11-17
11. [Weekly Tech+Bio #91: The Largest Venture Round in TechBio History](<https://www.techlifesci.com/p/weekly-techbio-91-the-largest-venture>), Weekly Tech+Bio, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661647/isomorphic-raises-record-5b-round-before-naming-a-development-candidate?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.biocentury.com/article/661645/sellas-aml-win-strengthens-case-for-cancer-vaccines-in-recurrence-prevention?utm_source=bc_rss&utm_medium=rss>
[3]: <https://www.biopharminternational.com/view/sellas-cancer-vaccine-galinpepimut-s-overall-survival-phase-3-regal-aml>
[4]: <https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/>
[5]: <https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&utm_medium=rss>
[6]: <https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>
[7]: <https://www.clinicaltrialsarena.com/news/aribio-ar1001-alzheimers-pill-phase-iii-polaris-ad/>
[8]: <https://www.pharmaceutical-technology.com/news/revolution-medicines-rasonque-ec-pancreatic-cancer/>
[9]: <https://www.pharmaceutical-technology.com/news/isomorphic-labs-5bn-advance-drug-pipeline/>
[10]: <https://european-biotechnology.com/latest-news/isomorphic-labs-raises-5b-six-months-after-2-1b-round/>
[11]: <https://www.techlifesci.com/p/weekly-techbio-91-the-largest-venture>
